Search results
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
NBC 10 - FOX 14 Monroe· 3 days agoThe study, which enrolled patients regardless of their CLDN18.2 and PD-L1 CPS expression, indicated encouraging efficacy data for the triple combination, especially in patients with high or ...
Cedars-Sinai Experts Present Cancer News at ASCO A | Newswise
Newswise· 2 days agoCedars-Sinai Cancer physician-scientists and thought leaders will discuss scientific advances, new therapies, and the future of cancer care at the American
Urine Tests Could Be 'Enormous Step' in Diagnosing Cancer
Medscape· 5 days agoThe next frontier in cancer detection could be the humble urine test. Emerging science suggests that...
Bob Nunnally reveals to NBC4 viewers what type of cancer he had
WCMH via Yahoo News· 2 days agoCOLUMBUS, Ohio (WCMH) — Bob Nunnally knows the difference between himself and the superhero...
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 2 days agoOther abstracts coming from the meeting include positive initial results from an ongoing Phase I/II...
Annual General Meeting in Cantargia AB
Digital Journal· 3 days agoAbout CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established ...
Memphis People in Business: May 23, 2024
Gannett via AOL· 3 days agoThe Kosten Foundation hosts a free, in-person and virtual pancreatic cancer support group in the Mid-South, which meets on the second Saturday of every...
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
Zacks via Yahoo Finance· 2 days agoCandel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with...
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 3 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 2 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...